Trump 2.0 presents opportunities and challenges for leaders of the biopharma industry, which needs effective public policy to thrive. On the latest BioCentury This Week, BioCentury Washington Editor Steve Usdin explains what those opportunities are, from modifying the Inflation Reduction Act to creating a friendlier deal-making environment under a new FTC commissioner. He also lays out the potential impact on the public policy environment, which could have repercussions on FDA, NIH, CMS and b...